Would you consider adjuvant chemotherapy in a young patient with stage IC1 Sertoli-Leydig cell tumor, moderately differentiated, with heterologous (rhabdosarcomatous) component and retiform elements?

This young patient has several high-risk criteria for recurrence. Thus, I favor offering her adjuvant systemic platinum-based chemotherapy with 6 cycles of carboplatin + paclitaxel.

Background:

Sertoli-Leydig cell tumors (SLCTs) are sex-cord stromal tumors and account for less than 0.5% of primary ova...